A small, preliminary study of an investigational new drug being studied for mild cognitive impairment and mild dementia associated with Alzheimer's disease suggests it is safe and may be associated with improvements in executive function, thinking and memory skills. The study is released today, March 31, 2022, and will be presented at the American Academy of Neurology's 74th Annual Meeting being held in person in Seattle, April 2 to 7, 2022 and virtually, April 24 to 26, 2022. The drug, called SAGE-718, is also in clinical trials for the treatment of cognitive impairment associated with Parkinson's disease and Huntington's disease.

More than 4 in 10 U.S. high school students said they felt persistently sad or hopeless during the pandemic, according to government findings released Thursday.

Residents of eastern Shanghai hoping to emerge from a four-day lockdown got some bad news Thursday night: Some will be confined to their homes for at least 10 more days.

A new study has found that the Novaplex SARS-CoV-2 Variant I, II, and IV real-time PCR assays (from Seegene Technology) can reliably detect SARS-CoV-2 in patient samples and identify known variants of interest and concern. Results from the PCR assays were comparable to those from the "gold standard" spike gene Sanger sequencing method. Researchers were also able to successfully streamline testing and reduce cost and turnaround time by processing samples without extracting RNA for testing. Their findings appear in The Journal of Molecular Diagnostics.

Researchers at the Yale Cardiovascular Data Science (CarDS) Lab have developed an artificial intelligence (AI)-based model for clinical diagnosis that can use electrocardiogram (ECG) images, regardless of format or layout, to diagnose multiple heart rhythm and conduction disorders.

Psychedelic drugs like psilocybin, an ingredient found in so-called magic mushrooms, have shown promise in treating a range of addictions and mental health disorders. Yet, there's something mysterious and almost mystical about their effects, and they are commonly believed to provide unique insights into the nature of consciousness.

In recent years, the number of people worldwide who are dissatisfied or anxious about their sleep has been increasing due to the diversification of lifestyles. Simple sleep measurement and quantitative understanding of individual sleep patterns are very important not only in the field of healthcare but also from the medical perspective, such as in the diagnosis of sleep disorders.

After following a group of patients with a specific gene mutation for many years, a team of UC Davis MIND Institute scientists has provided important insights into how fragile X-associated tremor/ataxia syndrome (FXTAS) first develops. The work, led by researchers David Hessl and Susan Rivera, identifies new ways to study the disease and possibly test potential therapies in the future. FXTAS, caused by "premutation" expansions of the FMR1 gene, has no approved treatments, only symptomatic management. The study was published in the Journal of Neurodevelopmental Disorders.

Lower suicide risk was seen in older adults aged 75+ residing in long-term care facilities who were prescribed antidepressants. Suicide risk was doubled in those who were on medication for sleep problems according to a study published in the International Journal of Geriatric Psychiatry.

Researchers of the Universitat Autònoma de Barcelona (UAB) in collaboration with the ALBA Synchrotron have studied the side effects of typical tooth whitening treatments based on oxidation compared to a new treatment developed by the authors through reduction. Results, published in Dental Materials, showed the whitening effect of the novel treatment to be highly improved in terms of application time needed, efficiency and safety, which makes it a promising candidate to develop novel whitening treatments. Experiments at the MIRAS beamline of ALBA helped to determine the chemical mineral modifications in the dental enamel.